Century Therapeutics Launches Type 1 Diabetes Program

Century Therapeutics ( (IPSC) ) just unveiled an announcement.

On November 13, 2025, Century Therapeutics announced the launch of its first program for Type 1 diabetes, CNTY-813, with plans to initiate IND-enabling studies by the end of 2025 and submit an IND in 2026. The company is also advancing CNTY-308 through IND-enabling studies for B-cell-mediated diseases, targeting clinical study initiation in 2026. Additionally, Century reported a net loss of $34.4 million for the third quarter of 2025, with a cash runway estimated to extend into the fourth quarter of 2027, reflecting a strategic focus on high-impact therapeutic areas and resource allocation.

The most recent analyst rating on (IPSC) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Spark’s Take on IPSC Stock

According to Spark, TipRanks’ AI Analyst, IPSC is a Neutral.

Century Therapeutics’ stock score is primarily influenced by its financial performance and technical analysis. The company is experiencing strong revenue growth but is not yet profitable, which is typical for the biotechnology sector. Technical indicators suggest positive momentum, but the valuation remains challenging due to negative earnings.

To see Spark’s full report on IPSC stock, click here.

More about Century Therapeutics

Century Therapeutics (NASDAQ: IPSC) is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies targeting autoimmune diseases and cancer. Their approach utilizes the iPSC cell foundry and Allo-Evasion™ technology to create off-the-shelf therapies aimed at expanding patient access and improving treatment outcomes.

Average Trading Volume: 874,354

Technical Sentiment Signal: Sell

Current Market Cap: $48.66M

For an in-depth examination of IPSC stock, go to TipRanks’ Overview page.